A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

To join this study, you would generally need to be between 50 and 90 years old and have been diagnosed with early Alzheimer's disease, or be experiencing mild memory problems thought to be due to Alzheimer's.

Researchers will need to confirm that changes in your brain are indeed linked to Alzheimer's, often through special scans. You'll also need to have someone, like a family member or close friend, who can act as a 'study partner' to help you throughout the study. Your memory and thinking abilities will be assessed to make sure you fit the study's specific criteria.

Not everyone can join, even if they have early Alzheimer's. For example, if you have other significant medical conditions that aren't well controlled, or if previous brain issues like a stroke or serious head injury could interfere with the study's results, you might not be suitable. A research doctor will carefully review your health to ensure the study is safe and appropriate for you.

If you decide to take part, you would receive either Trontinemab or a placebo. This would involve regular visits to the study clinic for check-ups, assessments of your memory and thinking, and scans like MRI to look at your brain. You might also have blood tests and spinal fluid tests (if appropriate and agreed upon) to help understand the disease and the treatment's effects. Your study partner would need to be available to attend some appointments with you and provide information about your memory and daily life. The exact number of visits and the total duration aren't specified here, but clinical trials usually involve a commitment over several months to a few years, with careful follow-up throughout.